NCT06364930View on ClinicalTrials.gov

SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus

PHASE4RecruitingINTERVENTIONAL
Enrollment

412

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

October 31, 2030

Study Completion Date

March 30, 2031

Conditions
Chronic Hepatitis B
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10mg Tab QD for 60 months.

DRUG

Placebo 10mg Tab

Placebo 10mg Tab QD for 60 months.

Trial Locations (1)

Unknown

RECRUITING

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER